-
2024-516418-39-00
5
2025-07-09
Multiple Myeloma
-
2024-516780-93-00
5
2025-07-09
Sustained immunosuppression
-
2024-515793-27-01
5
2025-04-30
HIV
-
2022-500455-23-00
5
2024-12-11
Candidemia
-
2023-504713-76-00
5
2024-12-03
Dermatitis atopic
-
2023-503859-10-00
5
2024-08-12
Moderate to Severe Plaque Psoriasis
-
2023-509905-62-00
5
2024-07-19
Lower limb trauma requiring immobilisation
-
2022-502276-23-00
5
2024-04-25
JAK2V617F-positive high-risk Polycythemia Vera
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
-
2024-516058-23-00
5
2023-12-18
Adult patients admitted to the ICU for management of severe influenza
-
2022-501710-62-02
6
2023-06-07
Peripheral T-cell lymphoma (PTCL)
-
2024-512759-19-00
4
2023-04-20
first suspected infection with Mycobacterium tuberculosis in the lungs
-
2024-511866-36-00
5
2023-03-11
patients hospitalized in ICU with ESBL-producing Enterobacteriaceae se
-
2024-513327-16-00
5
2022-09-20
Intensive care
-
2024-515354-24-00
9
2022-05-18
Low risk myelodysplastic syndrom without RS having failed or being ine
-
2024-513427-17-00
6
2021-05-20
Well controlled severe allergic asthma
-
2024-518578-15-00
5
2018-02-05
Is to demonstrate a non inferior efficacy of azithromycin and so the p
-
2024-516103-16-00
4
2015-12-04
Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
-
2024-516873-57-00
10
2026-01-13
Acute myeloid leukemia in adults aged 18 to 60
-
2024-512147-23-00
10
2024-11-21
Chronic Lymphocytic Leukemia
-
2023-504176-25-00
9
2024-08-08
Acute Myeloid Leukemia
-
2023-505972-32-00
5
2024-02-26
locally advanced anal squamous cell carcinoma
-
2023-505120-59-00
5
2023-12-19
Moderate to Severe Plaque Psoriasis